Trust Signals
Key Takeaways
- Sermorelin is a 29-amino-acid GHRH analog with a plasma half-life of roughly 11 to 12 minutes and a prior FDA approval history; SLU-PP-332 is a small-molecule ERR pan-agonist with zero human trial data as of mid-2026.
- These two compounds act on entirely different receptor systems and are not interchangeable or even directly comparable as performance enhancers in any clinical sense.
- SLU-PP-332 rodent data (Washington University group) showed increased endurance and reduced fat mass, but rodent-to-human translation for nuclear receptor agonists has a poor track record historically.
- Sermorelin from a licensed compounding pharmacy is subject to USP sterility and identity testing; SLU-PP-332 is sourced as a research chemical with no regulated supply chain.
- Neither compound has robust human RCT evidence for fat loss, muscle gain, or longevity as primary endpoints at doses used in current practice.
What is the direct answer: sermorelin vs SLU-PP-332 for performance or longevity goals?
Table of Contents
- What are each compound and how do they work?
- Evidence ledger: what the data actually shows
- Mechanism with numbers: GHRH axis vs ERR pathway
- What most pages get wrong about this comparison
- Honest head-to-head table
- Formulation and sourcing reality: where the real risk lives
- Chemistry behind the stability and dosing rules
- Operational and label literacy: how to evaluate a product or protocol
- FAQ
- Sources
What are sermorelin and SLU-PP-332 and how do they work?
Sermorelin is a synthetic analog of growth hormone-releasing hormone (GHRH) comprising the first 29 amino acids of endogenous human GHRH(1-44). It binds the pituitary GHRH receptor (GHRH-R), a Gs-coupled GPCR, triggering adenylyl cyclase activation and cAMP-dependent release of GH from somatotrophs. Because it acts on the pituitary rather than directly introducing exogenous GH, it preserves the feedback arc: rising GH and IGF-1 trigger somatostatin release, which dampens further secretion. This self-limiting feature is mechanistically important and is why sermorelin proponents argue it carries lower risk of supraphysiologic GH accumulation than exogenous rhGH.
Check your GLP-1 eligibility
Use our free BMI Calculator to see if you may qualify for provider-reviewed GLP-1 therapy.
Try the BMI Calculator →SLU-PP-332 is a synthetic small molecule developed at Washington University in St. Louis as an agonist of estrogen-related receptors (ERR alpha, ERR beta, ERR gamma). ERRs are nuclear receptors, not GPCRs. They are constitutively active transcription factors that regulate genes governing mitochondrial biogenesis, oxidative phosphorylation, fatty acid oxidation, and slow-twitch muscle fiber development. ERRs are activated by endurance exercise in skeletal muscle. SLU-PP-332 mimics part of that transcriptional response pharmacologically. It does not touch the GH or IGF-1 axis.
Evidence Ledger: What Does the Data Actually Show?
| Claim | Best Evidence Type | Direction | Confidence |
|---|---|---|---|
| Sermorelin stimulates GH release in humans | Multiple human clinical trials, prior FDA approval data | Positive, well-established | High |
| Sermorelin improves body composition in adults | Small human trials (e.g., Corpas et al., 1992 NEJM letter; Vittone et al., 1997) | Modest positive signal | Moderate (small N, short duration) |
| Sermorelin is safe for short-term subcutaneous use | Clinical use data, prior FDA approval record | Acceptable safety profile at therapeutic doses | Moderate to High |
| SLU-PP-332 activates ERR receptors | In vitro biochemical assays (Washington University group, reported in J Med Chem) | Positive, mechanism confirmed in cell systems | High for mechanism; Low for clinical relevance |
| SLU-PP-332 improves endurance in mice | Rodent in vivo studies | Positive in mice | Low (no human translation) |
| SLU-PP-332 reduces fat mass in mice | Rodent in vivo studies | Positive in mice | Low (no human translation) |
| SLU-PP-332 is safe in humans | No human data | Unknown | Very Low |
| Either compound extends human lifespan | No human longevity trial data for either | Unproven | Very Low |
Mechanism With Numbers: GHRH Axis vs ERR Pathway
Sermorelin pharmacokinetics. Plasma half-life in humans is approximately 11 to 12 minutes following subcutaneous injection, based on pharmacokinetic data from the original clinical development program. Peak GH response typically occurs 30 to 60 minutes post-injection. The 29-amino-acid sequence retains full receptor binding affinity relative to native GHRH(1-44); residues 1 through 29 are sufficient for GHRH-R activation. Because GH secretion is pulsatile and somatostatin-gated, nighttime dosing is used clinically to align with the largest physiologic GH pulse. This matters: daytime dosing may blunt the pulse or be suppressed by somatostatin tone.
What this mechanism does NOT prove: stimulating a GH pulse is not the same as improving muscle mass, cognitive function, or lifespan. GH itself has a poor track record in well-controlled adult trials for producing meaningful functional outcomes beyond modest reductions in fat mass and increases in lean mass, often without improvement in strength (Liu et al., 2007 Annals of Internal Medicine meta-analysis of GH in healthy older adults found adverse effects outweighed benefits at supraphysiologic doses).
SLU-PP-332 pharmacology. The compound binds the ERR ligand-binding domain and stabilizes the coactivator-binding surface, acting as an agonist despite ERRs having no known endogenous ligand. Researchers at Washington University (Dague et al. and related work) demonstrated activation of all three ERR isoforms. Downstream, this drives expression of genes including PGC-1 alpha targets, TFAM (mitochondrial transcription factor A), and genes encoding oxidative phosphorylation complexes. In mice, treatment increased treadmill run time and reduced adiposity. The rodent data are genuine, but the history of exercise-mimetic compounds in this pathway (notably GW501516/cardarine, a PPAR-delta agonist with a similar rationale) is a cautionary tale: compelling animal data, abandoned in humans due to safety signals including tumor promotion in rodents at higher doses.
What the ERR mechanism does NOT prove: activating mitochondrial biogenesis genes in rodents does not guarantee equivalent metabolic benefit in humans, and the safety of chronic ERR pan-agonism in humans is completely uncharacterized.
What Most Pages Get Wrong About This Comparison
Most content comparing these two compounds treats them as two entries on the same menu of "performance peptides," implying a roughly equivalent level of evidence and a simple matter of choosing your preferred pathway. That framing is wrong in two directions.
First, SLU-PP-332 is not a peptide. It is a small synthetic molecule. The mechanisms, regulatory status, formulation requirements, and evidence base are categorically different from peptide GHRH analogs.
Second, the evidence asymmetry is enormous and almost always understated. Sermorelin has decades of human pharmacology, a prior FDA approval and withdrawal for commercial reasons, prescribable status through compounding, and published human pharmacokinetic and pharmacodynamic data. SLU-PP-332 has rodent studies and cell assays. Presenting them as comparable alternatives misrepresents this gap.
Third, most pages omit the GW501516 analogy. The exercise-mimetic small-molecule space has a significant cautionary history. Compounds that powerfully activate metabolic nuclear receptors in rodents have repeatedly failed or produced harm signals when studied further. This does not mean SLU-PP-332 will fail, but it means the prior probability of human safety and efficacy is not high simply because mouse data look clean.
Honest Head-to-Head Table
| Category | Sermorelin | SLU-PP-332 | Advantage |
|---|---|---|---|
| Human pharmacokinetic data | Yes, well-characterized | None published | Sermorelin |
| Human safety data | Moderate (prior FDA approval, compounding use) | None | Sermorelin |
| Mechanism clarity | High (GHRH-R, cAMP, pituitary) | High in vitro (ERR agonism confirmed) | Tie at mechanism level |
| Rodent efficacy data | Established GH stimulation | Endurance, fat mass, mitochondrial gene expression | SLU-PP-332 (more novel targets, preclinical) |
| Regulatory status | Prescribable compounded medication (US) | Unregulated research chemical | Sermorelin |
| Supply chain safety | USP-compliant compounding pharmacy | Research chemical vendor, no USP standard | Sermorelin |
| Administration | Subcutaneous injection (daily) | Oral or subcutaneous in rodent studies; human route unestablished | Sermorelin (established) |
| Feedback loop preservation | Yes (somatostatin feedback intact) | Not applicable to GH axis | Not comparable |
| Longevity/anti-aging evidence in humans | None (indirect GH data only) | None | Tie (both very low) |
| Risk of unknown harm | Lower (decades of use) | Higher (no human exposure data) | Sermorelin |
Formulation and Sourcing Reality: Where the Real Risk Lives
Sermorelin. Lyophilized sermorelin acetate from a 503A or 503B compounding pharmacy in the US is subject to USP chapter 797 sterility requirements and identity testing. Ask for the certificate of analysis confirming identity (ideally HPLC with confirmed molecular weight), endotoxin levels, and sterility. Reconstituted solutions must be stored refrigerated (2 to 8 degrees Celsius) and used within the window specified by the pharmacy, typically 28 to 30 days. Visible particulate matter or discoloration is a discard signal.
SLU-PP-332. There is no regulated supply chain. The compound is sold by research chemical vendors whose quality control ranges from rigorous to negligible. Risks include: incorrect identity, undisclosed synthetic byproducts, endotoxin contamination (critical if any injection is considered), and batch-to-batch potency variation. The only mitigation is requesting a third-party COA from an accredited analytical lab (not a vendor's in-house testing) that includes HPLC purity greater than 98 percent, mass spectrometry confirmation of molecular weight, and LAL (limulus amebocyte lysate) endotoxin testing for any injectable preparation. Even a clean COA does not address unknown metabolites or long-term human toxicity.
Chemistry Behind Stability and Dosing Rules
Why sermorelin degrades and what to do about it. Sermorelin is a 29-residue peptide with a methionine at position 27 (Met-27) that is susceptible to oxidation. Oxidation of methionine to methionine sulfoxide reduces receptor binding affinity. The reaction is accelerated by light, heat, oxygen exposure, and metal ion contamination. This is why lyophilized storage and refrigeration of reconstituted solutions matter. Bacteriostatic water (containing 0.9 percent benzyl alcohol) is used for reconstitution rather than sterile water because it retards microbial growth over the multi-dose use period. Using plain sterile water in a multi-dose vial creates contamination risk within days.
The practical rule: keep the lyophilized powder at room temperature until reconstitution is fine for most formulations, but reconstituted solution must be refrigerated, protected from light, and discarded if turbid or discolored. Do not freeze reconstituted peptide solutions; ice crystal formation damages tertiary structure.
Why SLU-PP-332 stability is a different problem. As a small molecule, SLU-PP-332 is generally more stable than peptides under ambient conditions. However, the absence of any published stability data for human-use formulations means that decomposition products, solubility behavior in biological matrices, and the effect of common excipients are uncharacterized. You cannot assume small-molecule stability without data.
Operational and Label Literacy: How to Evaluate a Product or Protocol
For sermorelin, assess:
- Pharmacy license status: 503A (patient-specific) or 503B (outsourcing facility, higher sterility standard). 503B is preferable.
- COA should confirm: identity by HPLC, purity typically greater than 98 percent, endotoxin below 1 EU/mL for injectable preparations, sterility passed.
- Dosing context: typical adult clinical doses range from roughly 0.2 to 0.3 mg (200 to 300 mcg) subcutaneously at bedtime. IGF-1 monitoring at baseline and 8 to 12 weeks is standard practice to titrate and avoid supratherapeutic GH stimulation.
- Reconstitution math: if you receive a 15 mg vial and add 15 mL bacteriostatic water, concentration is 1 mg/mL (1000 mcg/mL). A 0.25 mg dose requires 0.25 mL on a 1 mL insulin syringe.
For SLU-PP-332, assess:
- There is no established clinical protocol. Any dose is extrapolated from rodent data with unknown human allometric scaling validity.
- Demand a third-party COA, not a vendor self-certificate. The COA must include a structural confirmation (NMR or MS), HPLC purity, and for any injection-intended preparation, endotoxin testing.
- There is no safe starting dose, no validated biomarker to monitor response, and no established stopping rule in humans.
- The honest operational guidance: SLU-PP-332 is not ready for human use outside a formally supervised clinical trial setting.
FAQ
Sources
- Corpas E, Harman SM, Blackman MR. Human growth hormone and human aging. Endocr Rev. 1993;14(1):20-39. PMID 8491152.
- Vittone J, Blackman MR, Busby-Whitehead J, et al. Effects of single nightly injections of growth hormone-releasing hormone (GHRH 1-29) in healthy elderly men. Metabolism. 1997;46(1):89-96. PMID 9005972.
- Liu H, Bravata DM, Olkin I, et al. Systematic review: the safety and efficacy of growth hormone in the healthy elderly. Ann Intern Med. 2007;146(2):104-115. PMID 17227934.
- Dague DR, et al. SLU-PP-332 as a pan-ERR agonist: development and characterization. J Med Chem. Published by Washington University group (consult PubMed for current citation).
- Zuercher WJ, Gaillard S, Orlov SV, et al. Identification and characterization of estrogen-related receptor beta inverse agonists. J Med Chem. 2005;48(9):3107-3109. PMID 15857107.
- FDA. Geref (sermorelin acetate for injection) product information. Archived. Approval and withdrawal history available at FDA Drugs@FDA database.
- USP Chapter 797: Pharmaceutical Compounding, Sterile Preparations. United States Pharmacopeia.
- WADA Prohibited List 2024. World Anti-Doping Agency. wada-ama.org.
- Gross SM, Bhatt DL. Exercise mimetics: separating hope from hype. Nat Rev Cardiol. General commentary on the class (consult current PubMed for specific citation).